Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/46293
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Karimnia N. | - |
dc.contributor.author | Wilson A.L. | - |
dc.contributor.author | Green E. | - |
dc.contributor.author | Matthews A. | - |
dc.contributor.author | Jobling T.W. | - |
dc.contributor.author | Plebanski M. | - |
dc.contributor.author | Bilandzic M. | - |
dc.contributor.author | Stephens A.N. | - |
dc.date.accessioned | 2022-02-10T23:55:53Z | - |
dc.date.available | 2022-02-10T23:55:53Z | - |
dc.date.copyright | 2021 | - |
dc.date.issued | 2021-09-10 | en |
dc.identifier.citation | Journal of Experimental and Clinical Cancer Research. 40(1) (no pagination), 2021. Article Number: 276. Date of Publication: December 2021. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/46293 | - |
dc.description.abstract | Background: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment. Method(s): CRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined "stemness" profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey's multiple comparison post hoc. Result(s): Leader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a "stemness" profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention. Conclusion(s): Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes.Copyright © 2021, The Author(s). | - |
dc.publisher | BioMed Central Ltd | - |
dc.relation.ispartof | Journal of Experimental and Clinical Cancer Research | - |
dc.subject.mesh | analysis of variance | - |
dc.subject.mesh | apoptosis | - |
dc.subject.mesh | *cancer cell | - |
dc.subject.mesh | cancer recurrence | - |
dc.subject.mesh | cancer stem cell | - |
dc.subject.mesh | cell division | - |
dc.subject.mesh | cell motility | - |
dc.subject.mesh | cell proliferation | - |
dc.subject.mesh | cell selection | - |
dc.subject.mesh | cell subpopulation | - |
dc.subject.mesh | cell viability | - |
dc.subject.mesh | chemosensitivity | - |
dc.subject.mesh | clustered regularly interspaced short palindromic repeat | - |
dc.subject.mesh | correlation analysis | - |
dc.subject.mesh | DNA replication | - |
dc.subject.mesh | drug screening | - |
dc.subject.mesh | enzyme degradation | - |
dc.subject.mesh | epithelial mesenchymal transition | - |
dc.subject.mesh | flow cytometry | - |
dc.subject.mesh | IC50 | - |
dc.subject.mesh | in vitro study | - |
dc.subject.mesh | live cell imaging | - |
dc.subject.mesh | nonparametric test | - |
dc.subject.mesh | *ovary cancer/dr [Drug Resistance] | - |
dc.subject.mesh | post hoc analysis | - |
dc.subject.mesh | promoter region | - |
dc.subject.mesh | protein expression | - |
dc.subject.mesh | real time polymerase chain reaction | - |
dc.subject.mesh | treatment outcome | - |
dc.subject.mesh | aldehyde dehydrogenase isoenzyme 1/ec [Endogenous Compound] | - |
dc.subject.mesh | *antineoplastic agent | - |
dc.subject.mesh | carboplatin/pd [Pharmacology] | - |
dc.subject.mesh | caspase 3/ec [Endogenous Compound] | - |
dc.subject.mesh | CD133 antigen/ec [Endogenous Compound] | - |
dc.subject.mesh | CD44v6 antigen/ec [Endogenous Compound] | - |
dc.subject.mesh | cisplatin/pd [Pharmacology] | - |
dc.subject.mesh | cyclophosphamide/pd [Pharmacology] | - |
dc.subject.mesh | cytokeratin 14/ec [Endogenous Compound] | - |
dc.subject.mesh | DNA/ec [Endogenous Compound] | - |
dc.subject.mesh | doxorubicin/pd [Pharmacology] | - |
dc.subject.mesh | epithelial cell adhesion molecule/ec [Endogenous Compound] | - |
dc.subject.mesh | fibronectin/ec [Endogenous Compound] | - |
dc.subject.mesh | green fluorescent protein | - |
dc.subject.mesh | Ki 67 antigen/ec [Endogenous Compound] | - |
dc.subject.mesh | nerve cell adhesion molecule/ec [Endogenous Compound] | - |
dc.subject.mesh | Notch receptor/ec [Endogenous Compound] | - |
dc.subject.mesh | octamer transcription factor 4/ec [Endogenous Compound] | - |
dc.subject.mesh | olaparib/pd [Pharmacology] | - |
dc.subject.mesh | paclitaxel/pd [Pharmacology] | - |
dc.subject.mesh | rucaparib/pd [Pharmacology] | - |
dc.subject.mesh | stem cell factor receptor/ec [Endogenous Compound] | - |
dc.subject.mesh | topotecan/pd [Pharmacology] | - |
dc.subject.mesh | transcription factor NANOG/ec [Endogenous Compound] | - |
dc.subject.mesh | transcription factor Slug/ec [Endogenous Compound] | - |
dc.subject.mesh | transcription factor Snail/ec [Endogenous Compound] | - |
dc.subject.mesh | transcription factor Twist/ec [Endogenous Compound] | - |
dc.subject.mesh | uvomorulin/ec [Endogenous Compound] | - |
dc.subject.mesh | vimentin/ec [Endogenous Compound] | - |
dc.subject.mesh | Wnt1 protein/ec [Endogenous Compound] | - |
dc.subject.mesh | *leader cell | - |
dc.title | Chemoresistance is mediated by ovarian cancer leader cells in vitro. | - |
dc.type | Article | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s13046-021-02086-3 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.pubmedid | 34470672 [http://www.ncbi.nlm.nih.gov/pubmed/?term=34470672] | - |
dc.identifier.institution | (Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australia | en |
dc.identifier.institution | (Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australia | en |
dc.identifier.institution | (Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australia | en |
dc.identifier.institution | (Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia | en |
dc.subect.keywords | article | - |
dc.subect.keywords | controlled study | - |
dc.subect.keywords | human | - |
dc.subect.keywords | human cell | - |
dc.subect.keywords | human tissue | - |
dc.identifier.affiliationext | (Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australia | - |
dc.identifier.affiliationext | (Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australia | - |
dc.identifier.affiliationext | (Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia | - |
dc.identifier.affiliationmh | (Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australia | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Obstetrics and Gynaecology (Monash Women's) | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.